Dr. Kevin Strange is an internationally recognized biomedical scientist, and entrepreneur. His research has been funded for more than 35 years by the National Institutes of Health, Department of Defense, and private foundations, and has been published in leading scientific journals including Science, PNAS, Neuron and Cell. He is the recipient of numerous awards including the John C. Parker Endowed Chair and Pittinger Award for Excellence in Basic Research. Dr. Strange earned his Ph.D. from the University of British Columbia and conducted postdoctoral training in membrane and renal physiology at the National Institutes of Health.
After a distinguished scientific and leadership career at Harvard Medical School and Vanderbilt University School of Medicine, Dr. Strange became the first president of the MDI Biological Laboratory in 2009 where he established the Kathryn W. Davis Center for Regenerative Biology and Medicine. The Davis Center was highlighted twice in the U.S. Congressional Record for its scientific accomplishments including the discovery of regenerative medicine drug candidates. Dr. Strange founded Revidia Therapeutics in 2013 to develop MSI-1436 and other small molecule regenerative medicine therapeutics.